Altimmune (ALT) Receivables - Net (2010 - 2026)

Altimmune (ALT) has 17 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 228.4% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 228.4% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 124.08% from the prior year.
• Receivables - Net for Q1 2026 stood at $1.7 million, up from $1.2 million in the prior quarter.
• Over the last five years, Receivables - Net for ALT reached as high as $1.7 million in Q1 2026 and fell as low as $136000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $578176.5 across 5 years, with a median of $428000.0 in 2024.
• Across the five-year window, Receivables - Net plunged 95.98% in 2022 and jumped 542.2% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $173000.0 in 2022, then soared by 542.2% to $1.1 million in 2023, then sank by 51.04% to $544000.0 in 2024, then soared by 124.08% to $1.2 million in 2025, then soared by 36.59% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $845000.0 in Q3 2025.